GlassScriptPhysician profile
Thomas J Boone
NPI 1346325750
$3,801.85
in general payments reported to CMS, 2019-2025
28 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $146 · 2021: $622 · 2022: $774 · 2023: $689 · 2024: $596 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $625.62 | 2019-2024 | |
| Amgen INC. | $616.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $463.35 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.94 | 2019-2025 | Jardiance |
| Abbvie INC. | $152.55 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $133.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $94.59 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $92.80 | 2019-2021 | |
| Lilly USA, LLC | $89.01 | 2019-2023 | Emgality, Jardiance |
| Phathom Pharmaceuticals, INC. | $88.76 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $65.57 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $51.73 | 2020-2024 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $47.00 | 2022 | |
| Astellas Pharma US INC | $38.94 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $35.15 | 2023-2025 | Korlym |
| Dexcom, INC. | $27.14 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $23.67 | 2020 | |
| Sanofi Pasteur INC. | $22.92 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.21 | 2024 | Dupixent |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Medtronic, INC. | $19.42 | 2023 | Osteocool Rf Ablation System |
| Lundbeck LLC | $15.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2019 | |
| Allergan, INC. | $13.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.41 | 2019 | |
| Shire North American Group INC | $11.89 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.